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Objectives To investigate long-term trends in antibiotic resistance of common bacterial
species isolated at a university hospital and in its intensive care units (ICUs).
Methods Levels of antibiotic resistance of common bacterial pathogens were investigated
at the Karolinska Hospital during the 12-year period 1988–99. Resistance rates were
analyzed for the entire hospital, as well as for ICUs combined.
Results At the Karolinska Hospital, we found increased ciprofloxacin resistance among
Escherichia coli isolates, from 0% in 1991 to 11% in 1999. In the ICUs, the corresponding
increase was from 0% to 4.8% during the same period. Co-trimoxazole resistance levels
increased from 7.5% to 14%, with lower levels for the ICUs. For ampicillin, cefuroxime,
and gentamicin, the levels of resistance were similar in the whole hospital and in the
ICUs. Among Pseudomonas aeruginosa isolates, imipenem resistance was higher in the
ICUs. For ciprofloxacin, resistance increased from 2.5% in 1991 to 13% in 1999 in the
whole hospital, with similar figures for the ICUs.
Conclusion The resistance rates at the Karolinska Hospital were still generally low, but
were increasing for some antibiotic–microbe combinations. The results emphasize the
importance of including all sectors of a hospital in resistance surveillance studies, and
also the value of long surveillance periods.
Keywords Antibiotic resistance, ciprofloxacin, Co-trimoxazole, Escherichia coli, Pseudo-
monas aeruginosa, resistance surveillance
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I N T R O D U C T I O N
The availability of a wide selection of antibacterial
drugs constitutes a therapeutic cornerstone in
modern medicine, providing effective therapy
for most bacterial infections, prophylaxis in surgi-
cal procedures with significant infection risks, and
the control of infections in immunocompromised
hosts. Until some 10–15 years ago, the number of
infectious diseases that could be cured or con-
trolled with antimicrobial drugs increased con-
tinuously [1], but during the last decade, the
combination of increasing antibiotic resistance
rates and the introduction of few truly new drugs
has reversed this favorable situation [1–5].
Emergence of resistance is seen in community
pathogens such as Streptococcus pneumoniae [5,6]
and Salmonella spp. [5,7], as well as in significant
hospital pathogens. Severe problems have been
particularly frequent within hospitals, notably in
units with a high consumption of antibiotics and a
high risk of spread of resistant bacteria, such as
intensive care units (ICUs) [8–10]. Resistance pro-
blems noted within ICUs may well be imported by
patients admitted from wards with a high inci-
dence of antibiotic resistance [11]. The emergence
of resistance can often be correlated with the over-
use of single or multiple antibiotic drugs [1–3,5,11–
14]. In previous studies, the incidence of antibiotic
resistance has generally been reported as low in
Sweden compared with most other examined
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areas [9,15,16], but recent studies have revealed
higher incidences in several ICUs [9,17].
In a recent US consensus statement on strategies
to prevent and control the emergence and spread
of antimicrobial-resistant microorganisms in hos-
pitals, one major point was ‘to develop a system to
recognize and promptly report significant changes
and trends in antimicrobial resistance’ [3]. At the
European Union (EU) conference ‘The Microbial
Threat’, in Copenhagen, Denmark in September
1998, surveillance of antimicrobial resistance and
antibiotic consumption was given high priority,
for the purpose of analyzing the present situation
regarding antibiotic resistance and establishing a
baseline for controlling the emergence of antibiotic
resistance [18]. The correct registration, reporting
and analysis of the resistance situation within a
hospital is the first step in halting the emergence of
antibiotic resistance [1,3,5,11]. Moreover, since
effective initial empirical therapy for severe infec-
tions is of decisive importance for the prognosis
[19,20], data on prevailing resistance rates for
different drugs are mandatory. We therefore
decided to analyze current and long-term trends
of antibiotic resistance within our hospital, includ-
ing separate analysis of trends for ICUs.
M A T E R I A L S A N D M E T H O D S
Karolinska Hospital
The Karolinska Hospital is a highly specialized
university hospital. There are altogether six ICUs
within the hospital. For comparisons of resistance
rates, only the non-pediatric ICUs were included,
i.e. the general surgery ICU (eight beds, increased
to 12 beds in 1998), the burns unit ICU (six beds,
reduced to four beds in 1991), the thoracic surgery
ICU (eight beds), and the neurosurgery ICU
(opened in 1996, 11 beds).
The total number of beds in the hospital was
reduced from 1325 in 1989 to 1132 in 1998, and the
number of inpatient bed-days from 339 547 in 1989
to 261 508 in 1998. The number of admissions,
however, increased from 42 801 in 1989 to
55 753 in 1998. Outpatient departments deal
mainly with referred patients.
Bacterial strains, culture media and species
identification
The results of susceptibility tests of clinical isolates
from the 12-year period 1988–99 were obtained
from the laboratory computer database. The total
number of cultures evaluated was between 36 496
and 54 919 annually, and 16 000–21 000 bacterial
isolates were included each year in our analysis,
which included pathogens collected from all types
of patient specimen. There were no trends in the
number of specimens obtained during the study
period. In order to avoid duplicate isolates, only
one isolate of the same species and type of speci-
men was included from each patient during each
year. This selection method was used in order to
ensure the inclusion of all blood isolates for which
extended antibiotic susceptibility results were
available. The validity of this procedure was
checked. When it was compared with a method
of including only one isolate of each species per
patient regardless of specimen, there were no
differences in resistance rates except for Pseudo-
monas aeruginosa and imipenem, which showed
slightly higher resistance figures with our selection
method. Identification of isolated organisms was
performed using standard methods [21,22]. Dif-
ferent name designations had been used for a few
species during different time periods, but were
aggregated under one correct species name. Spe-
ciation of enterococci was performed according to
the isolate and the patient status. The designation
‘Enterococcus species’ therefore contains both
Enterococcus faecalis and Enterococcus faecium iso-
lates. Pulsed-field gel electrophoresis (PFGE) was
used to identify isolates with similar patterns that
could be involved in imipenem-resistant Pseudo-
monas aeruginosa outbreaks [23].
Antibiotic susceptibility testing
The antibiotic susceptibilities of clinical isolates
were determined using the disk diffusion method
standardized according to the Swedish Reference
Group for Antibiotics (SRGA), with interpreta-
tions adjusted for species groups (http://www.
srga.org) [24,25]. The strains were inoculated onto
Oxoid Iso-Sensitest Agar (Oxoid AB, Sollentuna,
Sweden) or PDM agar (AB Biodisk, Solna,
Sweden) (PDM used during 1988–91). Antibiotic
disks were purchased from Oxoid AB or from AB
Biodisk (disks from Biodisk during 1988–91). Anti-
biotic disks were placed on the inoculated surface,
and this was followed by preincubation at room
temperature for 30 min and then by overnight in-
cubation at 36 8C  1 8C in air. Staphylococci were
tested for susceptibility to isoxazolylpenicillins
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with a 1-mg oxacillin disk or methicillin agar with
10 mg/L at 30 8C. Both methods were in use
throughout the study period, and were checked
regularly for accuracy. Resistant isolates were
examined by E test. Inhibition zone diameter
values were measured in millimeters with a pair
of callipers.
Antibiotics used for susceptibility testing varied
with the different microorganisms and specimen
types. For example, only urine isolates of Escher-
ichia coli were tested for susceptibility to ampicil-
lin, and only respiratory tract specimen, wound
and blood isolates for susceptibility to cefuroxime
and ciprofloxacin. E. coli urine isolates were tested
for ciprofloxacin susceptibility only in complicated
cases. Different classes of antibiotics were used in
different years [26]. The interpretation of susceptibi-
lity (SIR system: S ¼ susceptible, I ¼ intermediate
susceptibility, R ¼ resistant) followed guidelines
from the SRGA. These guidelines have adopted
species-related MIC limits, as well as species-
related zone diameter breakpoints [24,25,27]. With
species-related zone breakpoints, the I percentage
is minimized. Only isolates that were categorized
as R were included in the tables as percentage of
resistant isolates. The change of substrate in 1992,
from PDM agar (AB Biodisk) to Oxoid Iso-Sensit-
est Agar (Oxoid AB, Sollentuna, Sweden) did not
lead to changes in test performance or R category
breakpoints (see SRGA home page: http://www.
srga.org).
Control strains Staphylococcus aureus ATCC
29213 (CCUG 15915), E. faecalis ATCC 29212
(CCUG 9997), E. coli ATCC 25922 (CCUG 17620)
and P. aeruginosa ATCC 27853 (CCUG 17619)
(ATCC, American Type Culture Collection;
CCUG, Culture Collection of the University of
Gothenburg) were included to ensure reproduci-
bility of the antibiotic susceptibility testing proce-
dure [28].
R E S U L T S
Bacterial species recovered in 1988–99 at the
Karolinska Hospital and its ICUs
The isolation of various pathogenic bacterial spe-
cies at the Karolinska Hospital during the 12-year
period was first analyzed, with regard to both
absolute numbers and percentage of the total
number of bacterial isolates per year. The general
pattern observed was a slight shift from Gram-
positive organisms towards Gram-negative spe-
cies. There was a significant increase over time in
the bacterial species P. aeruginosa, Stenotrophomo-
nas maltophilia, E. coli, Citrobacter freundii, Serratia
marcescens, and Acinetobacter species (P < 0.04 to
P < 0.000002, Spearman rank order correlation).
Proteus vulgaris showed a slight but significant
decrease (P < 0.01). In the ICUs, there were no
significant changes over time for percentage occur-
rence of the common bacterial species. The most
common bacterial species registered in 1999 are
shown in Table 1 for both the Karolinska Hospital
and for its ICUs separately.
Antibiotic susceptibility results
Escherichia coli
A marked increase of resistance was seen for
ciprofloxacin, from 0% to 10.5% at the Karolinska
Hospital as a whole (P < 0.000001, Spearman rank
order correlation), and from 0% to 4.8% in the ICUs
(Table 2). The lower levels in the ICUs, compared
to the whole hospital, were explained by relatively
higher levels in some wards, particularly urology,
surgery, rehabilitation and oncology. Co-trimox-
azole resistance levels increased from 7.5% to
14.4%, with the levels for the combined ICUs
generally being somewhat lower. Ampicillin,
cefuroxime and gentamicin resistance rates essen-
tially fluctuated around 22.0%, 4.0% and 1.5%,
respectively, with lower resistance rates in the
ICUs for cefuroxime during the last 4 years
(Table 2). Cefotaxime and ceftazidime resistance
rates at the Karolinska Hospital as a whole never
exceeded 1.3%, and in the ICUs only one E. coli
strain was resistant to these drugs.
Klebsiella spp.
Ciprofloxacin resistance rates increased from 0.7%
to 4.0% at the Karolinska Hospital as a whole and
from 0% to 2.0% in the ICUs, from 1992 to 1999. For
co-trimoxazole, resistance levels showed fluctua-
tions independent of time between 0% and 7.3% at
the Karolinska Hospital as a whole and between
0% and 8.6% in the ICUs. Rates of resistance to
cefuroxime at the Karolinska Hospital as a whole
varied between 5.0% and 16%, and were never
higher in the ICUs.
Proteus mirabilis
Resistance to ciprofloxacin increased from 0% to
5.6% at the Karolinska Hospital as a whole, while
in the ICUs there was no resistance at all. For co-
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Table 1 The most common bacterial species isolated in 1999 at the Karolinska Hospital as a whole and in its ICUs
Organism
KH ICUs
No. % Rank No. % Rank
Escherichia coli 3484 21.01 1 103 7.62 4
Staphylococcus aureus 2625 15.83 2 169 12.51 3
Coagulase-negative staphylococci 2174 13.11 3 213 15.77 1
Enterococcus spp. 1796 10.8 4 115 8.51 2
Streptococcus group B 751 4.53 5 23 1.7 14
Haemophilus influenzae 703 4.24 6 73 5.4 5
Klebsiella pneumoniae 678 4.09 7 63 4.66 7
Pseudomonas aeruginosa 643 3.88 8 63 4.66 8
Streptococcus pneumoniae 597 3.60 9 33 2.44 9
Moraxella catarrhalis 514 3.10 10 24 1.78 13
Streptococcus group A 474 2.86 11 6 0.44 25
Enterobacter cloacae 362 2.18 12 66 4.89 6
Proteus mirabilis 285 1.72 13 18 1.33 17
Streptococcus group G 268 1.62 14 15 1.11 18
Klebsiella oxytoca 250 1.51 15 25 1.85 11
Acinetobacter spp. 162 0.98 16 25 1.85 12
Citrobacter freundii 126 0.76 17 10 0.74 19
Bacteroides fragilis 100 0.60 18 7 0.52 23
Stenotrophomonas maltophilia 84 0.51 19 20 1.48 15
Bacillus cereus 77 0.46 20 29 2.15 10
Morganella morganii 68 0.41 21 9 0.67 21
Proteus vulgaris 65 0.39 22 5 0.37 26
Bacteroides spp. 65 0.39 23 3 0.22 27
Serratia marcescens 62 0.37 24 20 1.48 16
Streptococcus group C 59 0.36 25 7 0.52 24
Enterobacter aerogenes 59 0.36 26 10 0.74 20
Bacillus spp. 54 0.33 27 8 0.59 22
Table 2 Proportions of resistance levels for Escherichia coli during 1988–99 shown as percentages
Year
Ampicillin
S  30/R  11
Piperacillin
S  21/R  17
Cefuroxime
S  19/R  15
Gentamicin
S  21/R  17
Ciprofloxacin
S  26/R  19
Co-trimoxazole
S  17/R  13
KH ICU KH ICU KH ICU KH ICU KH ICU KH ICU
1988 19.6 22.6 13.6 5.1 3.4 3.6 1.0 0.0 – – 7.5 6.0
1989 19.0 19.3 10.4 2.0 3.6 10 0.8 2.0 – – 7.9 2.9
1990 22.5 23.0 11.9 1.7 5.8 6.8 0.6 0.0 – – 7.6 3.6
1991 19.5 29.9 7.9 16.0 4.5 6.6 0.0 0.0 0.0 – 4.5 6.7
1992 18.5 25.8 14.3 –a 3.4 0.0 0.6 0.0 1.3 0.0 5.9 6.3
1993 21.5 19.2 10.8 – 3.0 1.6 0.5 0.0 2.5 0.0 7.9 1.7
1994 20.9 25.0 15.9 – 4.1 3.3 0.9 1.7 3.8 0.0 9.4 6.8
1995 22.1 21.2 6.7 2.6 4.3 4.3 1.5 0.0 5.1 4.6 11.0 7.6
1996 22.1 17.0 9.1 5.6 4.3 2.8 1.5 0.0 4.8 0.0 11.6 3.0
1997 23.7 24.5 9.5 2.4 3.9 1.2 1.2 1.2 7.0 1.3 11.8 7.8
1998 24.7 20.3 8.2 6.0 5.0 3.5 0.5 0.0 7.2 2.3 13.3 10.6
1999 26.5 28.3 23.7 15.1 5.3 3.5 2.4 2.3 10.8 4.8 14.4 6.2
Nb 2102 58 343 669 70 439 66 609 68
aNumber of isolates equal to or below 20.
bN ¼ mean number of isolates per year.
KH, Karolinska Hospital.
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trimoxazole, resistance levels fluctuated between
1.6% and 11%.
Pseudomonas aeruginosa
There was an increasing trend for ciprofloxacin
resistance in the entire Karolinska Hospital from
2.5% in 1991 to 12.5% in 1999 (P < 0.01, Spearman
rank order correlation) (Table 3). In the ICUs, there
was also an increase, but generally lower than that
for the whole hospital, and with fluctuations. An
even more marked resistance increase was seen for
imipenem; this was particularly noticeable in the
ICUs, where it fluctuated, but with peaks in 1991–92
and 1998–99, reaching 25% and 28% during the last
2 years. In the medical/surgical ICU, 14 patients in
1998 and 10 patients in 1999 were infected with
bacteria that were shown by PFGE analysis to
belong to one single clone representing nosoco-
mial outbreaks of imipenem-resistant isolates. It is
probable that the rise in resistance in 1991–92 was
also due to an outbreak, but data are not available
on the clonality of these isolates. The resistance to
ceftazidime never exceeded 1.5% at the Karolinska
Hospital during the study period. The resistance to
ceftazidime, piperacillin and gentamicin did not
exceed 2.2% at the Karolinska Hospital as a whole
and 4.9% in the ICUs after 1991 (Table 3).
Staphylococcus aureus
The methicillin resistance rate was below 1.1% at
the Karolinska Hospital as a whole and below 6.7%
in the ICUs during the last 8 years (mean values for
the last 8 years of the study period: Karolinska
Hospital as a whole 0.6%, ICUs 1.5%). Neither
gentamicin nor clindamycin resistance exceeded
3.6% for any year at the Karolinska Hospital. In the
ICUs, resistance to gentamicin was below 10%,
except for 1995 (19%), but with great fluctuations,
while resistance to clindamycin was below 6% in
all of the years except 1993 (9.1%). The resistance
level for fusidic acid was below 2.8% during
the last 4 years of the study period, both at the
Karolinska Hospital as a whole and in the ICUs.
D I S C U S S I O N
The results of the present study show that the
overall antibiotic resistance rates in our hospital
are still low in comparison with antibiotic resis-
tance in many other parts of the world [8,15,29–32].
The most important result in our studies was the
demonstration of differences in resistance levels
between the whole hospital and the ICUs. Parti-
cularly evident was the increased resistance to
ciprofloxacin among E. coli and P. aeruginosa
strains (Tables 2 and 3). For some antibiotic and
bacterial species, the resistance levels were high in
the ICUs, but even higher in other parts of the
hospital. Antibiotic resistance surveillance in the
hospital should therefore cover all wards. From an
international perspective, the prevalence of infec-
tions is usually higher in ICUs than in other wards,
Table 3 Proportions of resistance levels for Pseudomonas aeruginosa during 1988–99 shown as percentages
Year
Piperacillin
S  21/R  17
Gentamicin
S  21/R  17
Ciprofloxacin
S  32/R  24
Ceftazidime
S  23/R  19
Imipenem
S  23/R  19
KH ICU KH ICU KH ICU KH ICU KH ICU
1988 0.6 0.0 0.6 4.4 – – 1.2 0.0 0.0 –
1989 0.8 2.6 0.4 0.0 – – 0.4 2.6 – –
1990 4.4 16.3 5.9 16.3 – – 0.5 0.0 4.6 –
1991 1.7 4.9 2.0 4.9 2.5 0.0 0.4 0.0 2.5 10.3
1992 1.5 4.1 1.5 1.3 3.6 1.5 0.6 1.4 5.7 14.7
1993 0.5 0.0 1.8 1.3 8.8 2.9 1.0 1.3 4.3 6.6
1994 0.8 1.5 1.7 1.5 9.7 10.3 0.6 0.5 6.3 6.2
1995 0.6 1.9 0.9 3.8 7.8 6.4 0.3 0.0 3.7 3.8
1996 0.8 1.7 1.3 1.7 13.6 2.0 0.5 3.5 1.6 0.0
1997 0.9 2.3 1.6 4.4 8.9 6.2 0.2 0.0 5.0 13.3
1998 1.2 0.9 1.1 2.8 12 8.9 0.2 0.0 9.0 27.8
1999 2.2 3.5 1.0 0.0 12.5 3.9 1.5 2.3 9.9 25.3
Nb 377 65 378 65 376 65
aNumber of isolates equal to or below 20.
bN ¼ mean number of isolates per year.
KH, Karolinska Hospital.
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and nosocomial outbreaks are also more frequent
in ICUs [30,33,34]. Antibiotic consumption is con-
sequently relatively high in ICUs [35]. Because of
these factors, selection of resistant strains is
expected, and hence many antibiotic resistance
surveillance studies have been carried out in ICUs
only [9,10,36]. Only a few studies have compared
antibiotic resistance in ICUs and that in other
wards [8,30,37,38]. Therefore, this longitudinal
study design, comparing ICUs with the whole
hospital, is of value.
A few similar studies by others support the
present results. Archibald et al. noted differences
between ICUs and other healthcare facilities [8]. In
general, their results indicated higher resistance in
hospitals than in outpatient clinics. However, at
one hospital, there were higher resistance rates for
E. coli against ciprofloxacin and for P. aeruginosa
against imipenem in outpatients [8]. This was also
shown by Fridkin et al., who found a higher pre-
valence of quinolone-resistant P. aeruginosa in the
outpatient area [30]. These results are in contrast to
other reports, where resistant isolates in a hospital
were usually found in the ICUs [8,30,37–39]. Phase
one of the ICARE project suggested that most
antimicrobial resistance was to be found in the
ICUs of the hospital [8,38]. These results were
confirmed in phase two of the ICARE project [30].
The findings of less antimicrobial resistance for
some antibiotic and bacterial combinations in the
ICUs compared to the whole hospital might have
several explanations. Our ICUs are characterized
by short stays, and a majority of the cases are
hospitalized directly after emergency admittance.
This contrasts to the situation in ICUs in other
countries. Isolation care in general is essential to
prevent nosocomial transmission of infection and
colonization with resistant bacteria, and detailed
guidelines are available [40]. For the nursing of
potentially contagious cases, the importance of
good-quality barrier nursing [41], preferably in
single rooms [42], has been well documented as
a means to avoid the spread of resistant organisms.
Cross-transmission of multiresistant microorgan-
isms is common, particularly in ICUs [17,43]. If
transmission occurs, this is an indicator of poor
quality of nursing care, nursing overload and
crowding being most important [44]. At the Kar-
olinska Hospital, the reasons for lower resistance
rates may be sought among these circumstances.
Antimicrobial regimens were available and fairly
strictly followed, and most therapy was super-
vised daily by an infectious disease consultant.
The ICU patients also seem to be well protected
from transmission of infection/colonization by
good barrier nursing, except during periods of
overcrowding and understaffing.
Many published studies on antibiotic resistance
cover only shorter time periods [8,31,32,45]. We
found large fluctuations over time in our study,
indicating that it is important to perform antibiotic
resistance surveillance studies over longer time
periods. This is especially important for ICUs,
where the fluctuations seem to be more pro-
nounced. These fluctuations might be explained
partly as a result of outbreaks of nosocomial infec-
tions. The two outbreaks of imipenem-resistant P.
aeruginosa in the medical/surgical ICU occurred
during periods of overcrowding and understaffing
at the Karolinska Hospital. Moreover, previous
publications have given the results of multicenter
studies, with the data pooled from different cen-
ters [31,32,45,46]. Other studies have indicated that
a detailed analysis of the source of the data might
provide a more differentiated view of resistance
emergence [8]. Our data concerning ICU in rela-
tion to the whole hospital support this view. How-
ever, with the excellent barrier nursing in our
ICUs, the fluctuations cannot be fully explained
by outbreaks. Further analysis of antibiotic resis-
tance in ICUs should be performed at the Karo-
linska Hospital in order to answer these questions.
P. aeruginosa is a leading cause of nosocomial
infections [47]. Nearly half of the imipenem-resis-
tant P. aeruginosa strains were isolated from the
ICUs, which contained only 6% of the hospital
beds. The high prevalence of imipenem-resistant
P. aeruginosa among isolates from the ICUs has
been reported by other investigators [8,9,48].
Archibald et al. suggested some form of selection
effect among outpatients [8].The high ICU resis-
tance rates of 28% in 1998 and 25% in 1999 in our
studies were found to be due to an accumulation of
isolates from nosocomial outbreaks in the medi-
cal/surgical ICUs. Also, Tsakris et al. found the
high resistance to be due to an outbreak [49].
For the whole hospital, there was a slight shift
towards more Gram-negative isolates, particularly
P. aeruginosa, S. maltophilia, E. coli, C. freundii, S.
marcescens, and Acinetobacter species. A similar
trend was noted in another investigation, which
suggested that this increase might reflect the abil-
ity of these species to develop mutational resis-
tance to cephalosporins [50]. We found no shift to
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Gram-positive organisms as has been reported by
others [51,52].
The present study has shown that resistance
rates at the Karolinska Hospital are still generally
low, but that there have been increasing resistance
rates for some antibiotic–microbe combinations in
recent years. For some antibiotic and bacterial
species, the resistance levels were high in the ICUs
but even higher in other parts of the hospital,
emphasizing the importance of including all sec-
tors of a hospital in resistance surveillance studies.
There were considerable fluctuations in resistance
prevalence during the study period, especially in
the ICUs, illustrating the value of long surveillance
periods.
A C K N O W L E D G M E N T S
This work was supported by the AFA Health
Foundation, The Swedish Society of Medicine, and
the Richard Julins and Ruth Julins Foundation.
R E F E R E N C E S
1. Hart CA. Antibiotic resistance: an increasing
problem? It always has been, but there are things
we can do. BMJ 1998; 316: 1255–6.
2. Casadevall A. Crisis in infectious diseases: time for
a new paradigm? Clin Infect Dis 1996; 23: 790–4.
3. Goldmann DA, Weinstein RA, Wenzel RP et al.
Strategies to prevent and control the emergence and
spread of antimicrobial-resistant microorganisms in
hospitals. A challenge to hospital leadership. JAMA
1996; 275: 234–40.
4. Salyers AA, Amabile-Cuevas CF. Why are anti-
biotic resistance genes so resistant to elimination?
Antimicrob Agents Chemother 1997; 41: 2321–5.
5. Tomasz A. Multiple-antibiotic-resistant pathogenic
bacteria. A report on the Rockefeller University
Workshop. N Engl J Med 1994; 330: 1247–51.
6. Klugman KP. Pneumococcal resistance to antibio-
tics. Clin Microbiol Rev 1990; 3: 171–96.
7. Mirza SH, Beeching NJ, Hart CA. Multi-drug
resistant typhoid: a global problem. J Med Microbiol
1996; 44: 317–19.
8. Archibald L, Phillips L, Monnet D, McGowan Jr JE,
Tenover F, Gaynes R. Antimicrobial resistance in
isolates from inpatients and outpatients in the
United States: increasing importance of the inten-
sive care unit. Clin Infect Dis 1997; 24: 211–15.
9. Hanberger H, Garcia-Rodriguez JA, Gobernado M,
Goossens H, Nilsson LE, Struelens MJ. Antibiotic
susceptibility among aerobic gram-negative bacilli
in intensive care units in 5 European countries.
French and Portuguese ICU Study Groups. JAMA
1999; 281: 67–71.
10. Itokazu GS, Quinn JP, Bell-Dixon C, Kahan FM,
Weinstein RA. Antimicrobial resistance rates
among aerobic gram-negative bacilli recovered
from patients in intensive care units: evaluation of
a national postmarketing surveillance program.
Clin Infect Dis 1996; 23: 779–84.
11. Harbarth S, Pittet D. Multiresistance of gram-
negative bacteria in intensive care units: bad news
from without. Crit care Med 1999; 27: 1037–38.
12. Asensio A, Oliver A, Gonzalez-Diego P et al.
Outbreak of a multiresistant Klebsiella pneumoniae
strain in an intensive care unit: antibiotic use as risk
factor for colonization and infection. Clin Infect Dis
2000; 30: 55–60.
13. Carmeli Y, Troillet N, Karchmer AW, Samore MH.
Health and economic outcomes of antibiotic resis-
tance in Pseudomonas aeruginosa. Arch Intern Med
1999; 159: 1127–32.
14. de Man P, Verhoeven BA,Verbrugh HA, Vos MC, van
den Anker JN. An antibiotic policy to prevent emer-
gence of resistant bacilli. Lancet 2000; 355: 973–8.
15. Dornbusch K, King A, Legakis N. Incidence of
antibiotic resistance in blood and urine isolates
from hospitalized patients. Report from a European
collaborative study. European Study Group on
Antibiotic Resistance (ESGAR). Scand J Infect Dis
1998; 30: 281–8.
16. Dornbusch K. Resistance to beta-lactam antibiotics
and ciprofloxacin in gram-negative bacilli and
staphylococci isolated from blood: a European
collaborative study. European Study Group on
Antibiotic Resistance. J Antimicrob Chemother 1990;
26: 269–78.
17. Hanberger H, Hoffmann M, Lindgren S, Nilsson
LE. High incidence of antibiotic resistance among
bacteria in 4 intensive care units at a university
hospital in Sweden. Scand J Infect Dis 1997; 29:
607–14.
18. Wise R, Hart T, Cars O et al. Antimicrobial
resistance. Is a major threat to public health. BMJ
1998; 317: 609–10.
19. Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C.
Imipenem resistance of enterobacter aerogenes
mediated by outer membrane permeability. J Clin
Microbiol 2000; 38: 1048–52.
20. Kollef MH, Sherman G, Ward S, Fraser VJ.
Inadequate antimicrobial treatment of infections: a
risk factor for hospital mortality among critically ill
patients. Chest 1999; 115: 462–74.
21. Murray RE., Bdron EJ., Pfdller MA. et al. Manual of
clinical microbiology. Washington, DC: ASM Press,
1999.
22. Crichton PB. Enterobacteriaceae; Escherichia, Kleb-
siella, Proteus and other genera. In: Collee JG, Fraser
AG, Marmion BP, Simmons A, eds. Mackie and
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 388–396
394 Clinical Microbiology and Infection, Volume 9 Number 5, May 2003
McCartney, practical medical microbiology. New York:
Churchill Livingstone, 1996: 369.
23. Tenover FC, Arbeit RD, Goering RV et al. Interpret-
ing chromosomal DNA restriction patterns pro-
duced by pulsed-field gel electrophoresis: criteria
for bacterial strain typing. J Clin Microbiol 1995; 33:
2233–9.
24. Olsson-Liljequist B, Larsson P, Walder M, Mio¨rner
H. Antimicrobial susceptibility testing in Sweden.
III. Methodology for susceptibility testing. Scand J
Infect Dis Suppl 1997; 105: 13–23.
25. Ringertz S, Olsson-Liljequist B, Kahlmeter G,
Kronvall G. Antimicrobial susceptibility testing in
Sweden. II. Species-related zone diameter break-
points to avoid interpretive errors and guard
against unrecognized evolution of resistance. Scand
J Infect Dis Suppl 1997; 105: 8–12.
26. Barry AL, Thornsberry C, Jones RN, Fuchs PC,
Gavan TL, Gerlach EH. Reassessment of the ‘class’
concept of disk susceptibility testing. Cephalothin
disks versus minimal inhibitory concentrations
with eleven cephalosporins. Am J Clin Pathol 1978;
70: 909–13.
27. Olsson-Liljequist B, Forsgren A. Antimicrobial
susceptibility testing in Sweden. I. The work of
the Swedish Reference Group for Antibiotics
(SRGA and SRGA-M). Scand J Infect Dis Suppl
1997; 105: 5–7.
28. Kahlmeter G, Olsson-Liljequist B, Ringertz S.
Antimicrobial susceptibility testing in Sweden. IV.
Quality assurance. Scand J Infect Dis Suppl 1997; 105:
24–31.
29. Andrews J, Ashby J, Jevons G, Marshall T, Lines N,
Wise R. A comparison of antimicrobial resistance
rates in Gram-positive pathogens isolated in the UK
from October 1996 to January 1997 and October
1997 to January 1998. J Antimicrob Chemother 2000;
45: 285–93.
30. Fridkin SK, Steward CD, Edwards JR et al.
Surveillance of antimicrobial use and antimicrobial
resistance in United States hospitals: project ICARE
phase 2. Project Intensive Care Antimicrobial
Resistance Epidemiology (ICARE) hospitals. Clin
Infect Dis 1999; 29: 245–52.
31. Sahm DF, Marsilio MK, Piazza G. Antimicrobial
resistance in key bloodstream bacterial isolates:
electronic surveillance with the Surveillance Net-
work Database—USA. Clin Infect Dis 1999; 29: 259–
63.
32. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime
resistance among selected nosocomial gram-nega-
tive bacilli in the United States. National Nosoco-
mial Infections Surveillance System. J Infect Dis
1994; 170: 1622–5.
33. Widmer AF. Infection control and prevention
strategies in the ICU. Intensive Care Med 1994;
20(suppl 4): S7–11.
34. Trilla A. Epidemiology of nosocomial infections in
adult intensive care units. Intensive Care Med 1994;
20(suppl 3): S1–4.
35. Erlandsson CM, Hanberger H, Eliasson I et al.
Surveillance of antibiotic resistance in ICUs in
southeastern Sweden. ICU Study Group of the
South East of Sweden. Acta Anaesthesiol Scand 1999;
43: 815–20.
36. Vincent JL, Bihari DJ, Suter PM et al. The prevalence
of nosocomial infection in intensive care units in
Europe. Results of the European Prevalence of
Infection in Intensive Care (EPIC) Study. EPIC
International Advisory Committee. JAMA 1995;
274: 639–44.
37. Lucet JC, Decre D, Fichelle A et al. Control of a
prolonged outbreak of extended-spectrum beta-
lactamase-producing enterobacteriaceae in a uni-
versity hospital. Clin Infect Dis 1999; 29: 1411–18.
38. Monnet DL, Archibald LK, Phillips L, Tenover FC,
McGowan JE Jr, Gaynes RP. Antimicrobial use and
resistance in eight US hospitals: complexities of
analysis and modeling. Intensive Care Antimicro-
bial Resistance Epidemiology Project and National
Nosocomial Infections Surveillance System Hospi-
tals. Infect Control Hosp Epidemiol 1998; 19: 388–94.
39. Frank UJD, Lupke T. Antimicrobial susceptibility
among nosocomial pathogens isolated in intensive
care units in Germany. Eur J Clin Microbiol Infect Dis
2000; 19: 888–91.
40. Garner JS. Guideline for isolation precautions in
hospitals. The Hospital Infection Control Practices
Advisory Committee [published erratum appears
in Infect Control Hosp Epidemiol 1996; April; 17(4):
214]. Infect Control Hosp Epidemiol 1996; 17: 53–80.
41. Hartstein AI, Denny MA, Morthland VH, LeMonte
AM, Pfaller MA. Control of methicillin-resistant
Staphylococcus aureus in a hospital and an in-
tensive care unit. Infect Control Hosp Epidemiol 1995;
16: 405–11.
42. Jernigan JA, Clemence MA, Stott GA et al. Control
of methicillin-resistant Staphylococcus aureus at a
university hospital: one decade later. Infect Control
Hosp Epidemiol 1995; 16: 686–96.
43. Chetchotisakd P, Phelps CL, Hartstein AI. Assess-
ment of bacterial cross-transmission as a cause of
infections in patients in intensive care units. Clin
Infect Dis 1994; 18: 929–37.
44. Kibbler CC, Quick A, O’Neill AM. The effect of
increased bed numbers on MRSA transmission in
acute medical wards. J Hosp Infect 1998; 39: 213–19.
45. So¨rensen TL, Frimodt-Mo¨ller N, Espersen F. Use of
antimicrobials and resistance in bacteria isolated
from blood cultures in a Danish county from 1992
to 1995. Clin Microbiol Infect 1998; 4: 422–30.
46. Livermore DM, Threlfall EJ, Reacher MH et al. Are
routine sensitivity test data suitable for the surveil-
lance of resistance? Resistance rates amongst
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 388–396
So¨rberg et al Antibiotic resistance 395
Escherichia coli from blood and CSF from 1991–
1997, as assessed by routine and centralized testing.
J Antimicrob Chemother 1991; 45: 205–11.
47. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH.
Emergence of antibiotic-resistant Pseudomonas
aeruginosa: comparison of risks associated with
different antipseudomonal agents. Antimicrob
Agents Chemother 1999; 43: 1379–82.
48. Hanberger H, Nilsson LE, Claesson B et al. New
species-related MIC breakpoints for early detection
of development of resistance among Gram-negative
bacteria in Swedish intensive care units. J Anti-
microb Chemother 1999; 44: 611–19.
49. Tsakris A, Pournaras S, Woodford N et al. Outbreak
of infections caused by Pseudomonas aeruginosa
producing VIM-1 carbapenemase in Greece. J Clin
Microbiol 2000; 38: 1290–2.
50. Reacher MH, Shah A, Livermore DM et al.
Bacteraemia and antibiotic resistance of its patho-
gens reported in England and Wales between 1990
and 1998: trend analysis. BMJ 2000; 320: 213–16.
51. Cockerill FR 3rd, Hughes JG, Vetter EA et al.
Analysis of 281,797 consecutive blood cultures
performed over an eight-year period: trends in
microorganisms isolated and the value of anae-
robic culture of blood. Clin Infect Dis 1997; 24:
403–18.
52. Johnson AP. Antibiotic resistance among clinically
important gram-positive bacteria in the UK. J Hosp
Infect 1998; 40: 17–26.
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 388–396
396 Clinical Microbiology and Infection, Volume 9 Number 5, May 2003
